Axsome Therapeutics AXSM
United StatesHealthcare · BiotechnologyUSD
284.63 USD (+64.6%)
22 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Axsome Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the central nervous system, with one approved product (Sunosi) and a late-stage pipeline for migraine and other indications.
Key points
from its scores- ✓Strong growth9.8
- ✓Good share-price trend9.5
- ✕Little or no dividend0.5
- ✕Demanding valuation1.9
- ✕Little competitive advantage3.3
AI analysis
bottom line, main risk, context and newsHold in the portfolio only for investors with high risk tolerance and a long-term horizon, closely monitoring regulatory milestones and clinical trial data.
Axsome shows exceptional revenue growth of 45.5% and a gross margin of 93.2%, but it is still not profitable (operating margin -23.4%) and its valuation is demanding (forward P/E 34.4), making it a high-risk, high-reward story dependent on the success of its pipeline.
The main risk is the dependence on regulatory approval and the commercial success of its pipeline, especially AXS-07 for migraine, as a setback in clinical trials or at the FDA could sink the valuation of a company that is not yet profitable.
Context and risks
Commercial-stage biopharmaceutical company with a single approved product (Sunosi) and dependence on regulatory approval of its pipeline. Regulatory and product concentration risk is inherent to the business model, and the company is not yet profitable, amplifying the impact of any delay or setback in clinical trials or FDA decisions.
Is Axsome Therapeutics stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 241% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 108.6 | 4.1 | +2,543% |
| Price / sales | 11.7 | 3.4 | +241% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 1.9 out of 10 (median for Healthcare: 4.7).
Average analyst target: 284.63 USD, +64.6% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 3.3 (sector 5.5), Growth 9.8 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- 34.4
- EV / EBITDA
- −51.8
- Price / book
- 108.6
- Price / sales
- 11.7
- Market cap
- 9.1B USD
- Enterprise value
- 9.0B USD
Profitability
- ROE
- −245.1%
- ROA
- −16.3%
- ROIC (approx.)
- −59.0%
- Gross margin
- 93.2%
- Operating margin
- −23.4%
- Net margin
- −24.7%
- Free cash flow
- −4.6M USD
- FCF yield
- −0.1%
Solvency
- Total debt
- 224.7M USD
- Net debt
- −95.2M USD
- Cash
- 319.8M USD
- EBITDA
- −172.9M USD
- Net debt / EBITDA
- 0.55
- Debt / equity
- 269.73
- Current ratio
- 1.43
- Quick ratio
- 1.30
Growth
- Revenue growth
- +45.5%
- EPS (TTM)
- −3.74 USD
- EPS (forward)
- 5.03 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 0.85
- Analyst consensus
- Strong buy (22)
- Target price
- 284.63 USD
- 52-week range
- 117.30 – 260.19
Recent news
All AXSM news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Axsome Therapeutics
Is Axsome Therapeutics stock cheap or expensive?
On Price / sales, it trades 241% above the Healthcare median. Valuation score: 1.9 out of 10 (median for Healthcare: 4.7). Average analyst target: 284.63 USD, +64.6% versus the price. This is not investment advice.
What score does Axsome Therapeutics get on MeridIAn Screener?
It scores 4.9 out of 10, rank 1,726 of 2,130 (better than 17% of the companies analysed). Its strongest category is Growth (9.8) and its weakest, Dividend (0.5). Analysis of 08/10/2026.
How much is Axsome Therapeutics worth on the stock market?
Its market capitalisation is 9.1B USD and its enterprise value, debt included, is 9.0B USD.
How much debt does Axsome Therapeutics have?
It has more cash than debt: net cash of 95.2M USD.
Does Axsome Therapeutics pay a dividend?
It pays no dividend, or almost none.
How has Axsome Therapeutics stock performed over the last year?
It has risen 42.1% over the last year, excluding dividends. Over the last 52 weeks it has traded between 117.30 and 260.19 USD. Past performance does not guarantee future results.
What do analysts think of Axsome Therapeutics?
22 analysts cover it; their average recommendation is “Strong buy” and their average target is 284.63 USD (+64.6% versus the price). It is an estimate, not market data.